- Bone Health
- Immunology
- Hematology
- Respiratory
- Dermatology
- Diabetes
- Gastroenterology
- Neurology
- Oncology
- Ophthalmology
- Rare Disease
- Rheumatology
The Top 5 Biosimilars Articles for the Week of November 11
The Center for Biosimilars® recaps the top stories for the week of November 11, 2019.
Transcript
Hi, I’m Christina Mattina for The Center for Biosimilars®, your resource for clinical, regulatory, business, and policy news in the rapidly changing world of biosimilars.
Here are the top 5 biosimilars articles for the week of November 11, 2019.
Number 5: A new study shows the extent to which financial hardship is impacting seriously ill Medicare beneficiaries.
Number 4: During the FT Global Pharmaceutical and Biotechnology Conference, Celltrion gave a look at its plans for CT-P13.
Number 3: Prescription drug prices are now front and center in the push to make health insurance coverage more affordable to provide to American workers.
Number 2: Price hikes alone accounted for most recent spending growth on biologics, according to research presented at the American College of Rheumatology’s 2019 annual meeting.
Number 1: On Monday, the first biosimilar rituximab began to reach US oncology patients.
Finally, last week, our e-newsletter asked whether you are optimistic that Stephen Hahn, MD, will be proactive about biosimilars if he is confirmed as the next FDA Commissioner.
To view results of the poll, visit us on LinkedIn.
To read all of these articles and more, visit centerforbiosimilars.com.
Eye on Pharma: Korean Drugmakers’ Impact in Europe; New Denosumab, Eculizumab Deals
January 11th 2025Korean drugmakers hold over 50% market share in the 6 best-selling biosimilar markets, 2 companies sign exclusive licensing partnership for a denosumab biosimilar, and 2 others join forces for an eculizumab biosimilar.
Biosimilars Policy Roundup for September 2024—Podcast Edition
October 6th 2024On this episode of Not So Different, we discuss the FDA's approval of a new biosimilar for treating retinal conditions, which took place in September 2024 alongside other major industry developments, including ongoing legal disputes and broader trends in market dynamics and regulatory challenges.
The Top 5 Most-Read Policy Articles of 2024
December 28th 2024The top biosimilar policy articles of 2024 highlight advancements that include FDA guidance to simplify biosimilar interchangeability and CMS drug price negotiations under the Inflation Reduction Act, alongside challenges posed by pharmacy benefit manager rebate practices and the need for more active stakeholder engagement.
How Vertical Integration Drives Innovation and Access in Biosimilars
December 27th 2024Elie Bahou, PharmD, highlights how vertical integration in the biosimilar industry streamlines costs, improves supply reliability, accelerates market adoption, and enhances patient access, while emphasizing the value of collaboration, quality control, and value-based contracts for sustainable health care delivery.
